Drug Shortage Report for APO-RISEDRONATE
| Report ID | 58626 |
| Drug Identification Number | 02353687 |
| Brand name | APO-RISEDRONATE |
| Common or Proper name | RISEDRONATE |
| Company Name | APOTEX INC |
| Market Status | MARKETED |
| Active Ingredient(s) | RISEDRONATE SODIUM |
| Strength(s) | 35MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 30 BTL |
| ATC code | M05BA |
| ATC description | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2018-08-20 |
| Estimated end date | Unknown |
| Actual end date | 2018-10-18 |
| Shortage status | Resolved |
| Updated date | 2018-10-19 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 150 SIGNET DRIVE TORONTO, ONTARIO CANADA M9L 1T9 |
| Company contact information | Apotex Customer Service - 1-877-427-6839 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2018-10-19 | French | Compare |
| v3 | 2018-10-19 | English | Compare |
| v2 | 2018-08-21 | French | Compare |
| v1 | 2018-08-21 | English | Compare |
Showing 1 to 4 of 4